- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Diplomat becomes distributor of recently approved cancer drug
PHILADELPHIA — Lannett has received regulatory approval from the Food and Drug Administration for its version of an antipsychotic treatment.
The drug maker said the FDA approved its abbreviated new drug application for loxapine capsules in the 5-mg, 10-mg, 25-mg and 50-mg strengths. The drug is a generic version of Watson Pharmaceuticals' Loxitane.
“We have now received five product approvals from the FDA over the last three months,” Lannett president and CEO Arthur Bedrosian said. “Loxapine capsules is an important addition to our product lineup.”